Minimally Invasive Groin Dissection for Melanoma
NCT01500304 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88
Last updated 2018-03-23
Summary
The purpose of this this study is to determine if a structured educational training program is successful in teaching surgeons a new operative technique. It will then be determined if this new operative technique is safe.
Conditions
Interventions
- PROCEDURE
-
Minimally invasive inguinal lymph node dissection
Operative intervention will be a minimally invasive inguinal lymphadenectomy, which is a three trocar technique to the inguinal dissection, that respects the same anatomic boundaries as the conventional open procedure
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
James Jakub, MD · Mayo Clinic
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2015-12-31
- Completion
- 2015-12-31
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma
NCT02166788 ·Status: COMPLETED ·Phase: PHASE3
-
Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis
NCT03949153 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes
NCT00463892 ·Status: COMPLETED ·Phase: PHASE2
-
Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy
NCT02857374 ·Status: COMPLETED ·Phase: NA
-
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
NCT01511913 ·Status: COMPLETED
-
Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node
NCT06754904 ·Status: RECRUITING ·Phase: NA
-
Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma
NCT01840007 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
NCT00627419 ·Status: TERMINATED ·Phase: PHASE2
-
One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy
NCT06809491 ·Status: ACTIVE_NOT_RECRUITING
-
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
NCT05289193 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Pembrolizumab and Cryoablation in People With Mesothelioma
NCT05071014 ·Status: COMPLETED ·Phase: PHASE1
-
Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
NCT01253096 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma
NCT01996202 ·Status: COMPLETED ·Phase: PHASE1
-
A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients
NCT07068074 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment
NCT01920516 ·Status: UNKNOWN
-
Ipilimumab + Temozolomide in Metastatic Melanoma
NCT01119508 ·Status: COMPLETED ·Phase: PHASE2
-
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
NCT06400550 ·Status: RECRUITING
-
Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
NCT05406466 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
NCT00057616 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma
NCT00001296 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma
NCT01608594 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
NCT02821000 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
NCT02009397 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Tracing Dissemination of Melanoma Cells in Healthy Tissues
NCT02854124 ·Status: COMPLETED
-
ADI-PEG in Patients With Metastatic Melanoma
NCT00029900 ·Status: COMPLETED ·Phase: PHASE1